Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$0.67 USD
0.00 (-0.30%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.67 0.00 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Gossamer Bio, Inc. [GOSS]
Reports for Purchase
Showing records 1 - 20 ( 63 total )
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Seralutinib''s Phase 3 PAH Program Progressing on Track; ATS 2024 Should Accelerate Momentum; 4Q23 Results; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY23 Financials; Topline Ph3 PROSERA Data for Seralutinib/PAH in Q4:25
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Seralutinib''s Phase 3 PAH Program Progressing on Track;ATS 2024 Should Accelerate Momentum; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Positive Durability Data, a Blockbuster Hire, and Favorable Read-Throughs to Start the Year; Upping PT to $10; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Ph2 OLE Update: Like Fine Wine Seralutinib''s Profile Gets Even Better Over Time
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Lead Program Seralutinib Progressing in Phase 3 PAH Program Ahead of Plan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q3: Ph3 PROSERA Trial Progress; TORREY FRI Sub-Study Data Presented at ERS 2023
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Seralutinib Nearing Phase 3 Study Start; Additional Phase 2 OLE Data Expected 4Q23 or 1Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Q2:23 Financials; Progressing Towards PROSERA, Ph3 Initiation in Q3
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Company: Gossamer Bio, Inc.
Industry: Medical - Biomedical and Genetics
Seralutinib Generates Compelling Phase 2 OLE Interim PAH Data; Phase 3 Details Emerge; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P